Plasma sarcosine does not distinguish early and advanced stages of prostate cancer by Bohm, L. et al.
RESEARCH
677  August 2012, Vol. 102, No. 8  SAMJ
The identification of prostate cancer remains problematic; no 
single, simple procedure exists for a reliable diagnosis. Prostate 
specific antigen (PSA), while non-invasive and easily measurable in 
serum, is not specific owing to false-positives from benign prostatic 
hyperplasia (BPH), inflammatory conditions and prostatic trauma. 
Additional diagnostic information must therefore be obtained by 
transrectal ultrasonography (TRUS) and digital rectal examination 
(DRE) to assess prostate size and morphology. Final confirmation of 
a malignancy requires histopathological analysis of several biopsies. 
A remaining hurdle in the identification process is the existence of 
indolent organ-confined disease and aggressive metastatic prostate 
cancer that can only be distinguished by additional imaging or 
nuclear medicine procedures.
In a new approach to this diagnostic dilemma, it has been argued 
that screening for changes in metabolite expression resulting from 
gene silencing and gene activation could be used to identify a 
specific biological marker that increases in the transformation 
process. Therefore, a paper elaborating on metabolite expression 
in clinical samples of benign, localised and metastatic prostate 
cancer1 was enthusiastically received and debated in editorials.2-5 
The proposal that sarcosine (N-methylglycine) (a metabolite of 
choline found in urine) may be characteristic for prostate cancer 
progression has since been examined in other laboratories.1 These 
investigations found sarcosine levels in urine6 and serum7 to be 
constant, irrespective of sample pathology. From our own and 
published preliminary measurements, it is nevertheless clear that 
sarcosine-alanine ratios in prostate tumour patients are often 
elevated above controls and are spread over a wider range.1,7,17 A 
relationship between sarcosine and disease therefore cannot as 
yet be totally ruled out. Interest in sarcosine as a marker molecule 
remains topical, as shown by a recent modification of sarcosine 
assay by GC/MS in urine.8
We present measurements in plasma of prostate cancer patients 
characterised by PSA, tumour stage and Gleason score using GC/MS 
for sarcosine methodology9,10 to elaborate further on the suitability of 
sarcosine as a marker for prostate cancer.
Methods
Patient blood was collected by venipuncture and centrifuged, and 
clear supernatants were stored at -20°C. The AxSYM total PSA was 
determined by a MEIA microparticle enzyme immune assay (Abbott) 
and expressed as ng/ml. Ethical approval was granted by the University 
of Stellenbosch Health Research Ethics Committee (N09/11/330).
Sarcosine and alanine were quantified in plasma by gas-
chromatograph mass spectrometry. Briefly, amino acids were 
extracted from 100 µl of acidified plasma by solid phase extraction 
onto a cation exchange column before being washed, eluted and 
derivatised to their corresponding alkyl chloroformates using a 
commercial kit (EZ:faast, Phenomenex, Torrance CA, USA). After 
derivatisation, the amino acids were extracted into solvent and 2 µl 
injected into an Agilent 7890A/5975C GCMS system fitted with a 
Zebron ZB AAA 10 m x 0.25 mm capillary GC column. The sample 
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Introduction. Diagnosis of prostate cancer by prostate specific 
antigen (PSA) is error-prone and cannot distinguish benign 
prostatic hyperplasia (BPH) from malignant disease, nor identify 
aggressive and indolent types.
Methods. We determined serum sarcosine (N-methylglycine) in 
328 cancer patients by gas chromatography (GC)/mass spectroscopy 
(MS) and searched for correlations with early (stage T1/T2) and 
advanced (stage T3/T4) disease.
Results. Serum sarcosine of male control patients ranged from 1.7 
µmol/l to 4.8 µmol/l. In prostate cancer patients, sarcosine ranged 
from 2.8 µmol/l to 20.1 µmol/l. Expressed as the sarcosine/alanine 
ratio, serum control values were 9.4±5.5x10-3 (mean±SD) compared 
with 21.6±9.0; 28.5±16.6; 22.7±7.7 and 22.2±11.0 for patients 
diagnosed with T1, T2, T3 and T4 prostate tumours, respectively. 
The small differences between T1, T2, T3 and T4 patients were 
not statistically significant (p=0.51). However, the conventional 
PSA marker significantly correlated with T stage in these patients 
(r=0.63; p<0.009).
Conclusions. The median sarcosine/alanine ratios among patients 
with early and advanced prostatic cancer ranged from 21.6±9.0 
to 28.5±16.6 and were fairly constant, showing no statistically 
significant differences between T-stages. The results are consistent 
with published data in urine and serum which find differences 
between controls and patients with metastatic prostate cancer to be 
small and sarcosine to be uninformative regarding prostate cancer 
progression. By multi-comparison of PSA with T-stages in the same 
group of patients, we found significant correlations confirming the 
well-known merits and limitations of this marker.
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was injected at a 1:10 split and 250°C. Helium was used as the carrier 
gas at 1.65 ml/min, and the column heated from 110°C to 320°C at 
30°C per minute. The amino acids were quantified using a norvaline 
internal standard against standard curves generated from traceable 
calibrators using the following ions and (qualifier ions): alanine – mz 
130, sarcosine – mz 217, and norvaline – mz 158. Fig. 1 demonstrates 
a total ion chromatogram obtained from an equimolar 20 µmol/l 
solution of amino acids. Abundance of alanine in plasma was used as 
the internal reference, and all results were expressed as the sarcosine/
alanine ratio, as previously suggested.1
Results
Absolute sarcosine levels in serum/plasma of male control patients 
were found to be in the range of 1.7 - 4.8 µmol/l while alanine used 
as the internal standard was in the range of 301 -553 µmol/l. To 
circumvent variations owing to diet and metabolic factors, sarcosine 
is now commonly expressed as the sarcosine/alanine ratio. The 
median sarcosine/alanine ratios in tumour patients were fairly 
constant and in the range of 15 - 25 x10-3. Within a given tumour 
category, e.g. T2, sarcosine/alanine ratios can vary by factors as 
high as 10, while the median sarcosine/alanine ratios in early and 
advanced tumours remain in a fairly narrow range of 15 - 25 x10-3 
with a trend towards lower values in the T3/T4 group of tumors (Fig. 
2). The sarcosine results were obtained in plasma of patients who 
had undergone transurethral resection (TURP) to alleviate urinary 
obstruction. Of these patients, 27% had benign prostatic hyperplasias 
(BPH) and were not entered for sarcosine analysis. Samples entered 
for sarcosine determination fell into 2 groups: tumour stages T1 
and T2, Gleason score <7; and advanced tumours T3 and T4 with 
a Gleason score >7. Fig. 2 shows sarcosine/alanine ratios in the 
T1/T2 group of patients to be higher than in the T3/T4 group of 
patients. Two-tailed multiple comparison of sarcosine/alanine ratios 
with T-stages by Kruskal-Wallis multiple comparison test dialogue 
indicated that the differences between medians were not statistically 
different (p=0.51).
Examining the relationship between tumour stage and PSA in a 
larger contingent of patients (N=325), we found PSA to be well below 
200 ng/ml for the T1 and T2 group of patients, reaching 1 200 ng/ml 
in the T3 and T4 group of patients. PSA and T stage were significantly 
correlated (r=0.63 and p<0.009). Data for percentage free PSA were 
not available in our patients. By Kruskal-Wallis multiple comparison, 
we found that the PSA in T1 patients differed significantly from T3 
and T4, and T2 differed from T4, while PSA did not separate T2 from 
T3 and T1 from T2 (Table 1, Fig. 3).
Discussion
Using urine samples, Jentzmik et al. found the sarcosine/creatinine 
ratios in patients with prostatectomy-based Gleason score <7 and 
Gleason score >7 not to be statistically different.6 Since sarcosine 
in urine is due to renal excretion, urine may not be a representative 
body fluid.6 Therefore, plasma may be a better source of abnormal 
metabolite expression. Following this reasoning, Struys et al. 
determined sarcosine in plasma from controls, localised prostate 
cancer, and metastatic castration-resistant prostate cancer. In this 
study, the mean sarcosine concentration was found to be at the level 
of 2.0 µmol/l with no statistical differences between the 3 sample 
categories.7 Our results (Fig. 2) are consistent with the findings on 
urine6 and serum7 and show that, where prostate cancer is manifest, 
the sarcosine/alanine ratio cannot distinguish early and advanced 
disease. Specific alterations of sarcosine metabolism exist in folate 
Fig. 2. Box plots of sarcosine/alanine ratios against T-status. Data were 
subjected to Kruskal-Wallis test T1 (N=20), T2 (N=17), T3 (N=11) and 
T4 (N=10). Differences between medians were not statistically significant 
(p=0.51).
Table 1. Kruskal-Wallis multiple comparisons of PSA per T-stage, showing individual p-values*
PSA T1 T2 T3 T4
T1 0.173478 0.005280 0.000002
T2 0.173478 1.000000 0.010383
T3 0.005280 1.000000 0.523807
T4 0.000002 0.010383 0.523807
*See Fig. 3.
Fig. 1. Total GC/MS ion chromatogram of a 20 µmol/l solution of amino 
acids demonstrating the separation in plasma. N-methylglycine (sarcosine) 
retention time is 1.38 minutes. Peak at 1.53 is α-amino-butyric acid.
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and in N-methylglycine-transferase deficiency where sarcosine 
reaches levels as high as 49.3 µmol/l.13
Jentzmik et al. pointed out in their analysis of urine sediments6 that 
the sarcosine/creatinine ratios were insensitive to rectal palpation, 
in contrast with Sreekumar’s original findings1 that observed such 
sensitivity. That sarcosine correlates with invasion and performs 
better than PSA to distinguish diagnostic classes in the grey zone of 
2 - 10 ng/ml PSA1 also could not be corroborated.6 The controversy 
about sarcosine as a new diagnostic marker has been debated in an 
editorial14 and several letters.15-18
A consistent observation in our analysis is that the sarcosine-
alanine ratios within patient groups can vary as much as 10 times, 
e.g. in T2 patients (Fig. 2). The median T1, T2, T3 and T4 ratios were 
found to be in the range of 15 - 25x10-3 and to be fairly constant, 
showing no statistically significant differences. Publications on urine 
sediments showed sarcosine-alanine ratios to be higher than in 
serum and to vary from 70x10-3 in controls to 100x10-3 in prostate 
cancer patients, and a 2 - 3 times variation of ratios within groups.17 
From our data, we conclude that sarcosine has little merit as a 
biomarker and can give no useful additional information on prostate 
cancer progression. Also not supported is proof of the concept of 
sarcosine as a potential biomarker put forward in the exchange of 
views on sarcosine.17
The failure of sarcosine as a marker for prostate cancer prompted 
us to re-examine the diagnostic merits of PSA, using data from our 
teaching hospital at Tygerberg. PSA separates the T1 - T2 from the T3 
- T4 group of tumours rather well (Fig. 3, Table 1). These results are 
in agreement with extensive PSA data showing that mean and median 
PSA values indeed differ between T-stages where they serve as a 
valuable indicators in the management of the disease.19,20 Our results 
add to the growing realisation that sarcosine as a potential biomarker 
of prostate cancer progression may not live up to expectations.
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Fig. 3. Box plot of PSA against T-stage. PSA separates T1/T2 tumours from 
T3/T4 tumours. T1 N=89, T2 N=80, T3 N=78, and T4 N=78. By Kruskal-
Wallis test, T1 was found to be statistically different from T3 and T4; T2 
was found to be statistically different from T4 only, and T3 was statistically 
different from T1.
